Table 1.

Demographic characteristics of patients included in the study, stratified by occurrence of the three MEN1 main tumors.

Demographic characteristic	Total patients (n  = 101)	Patients with PHPT (n  = 76)	Patients without PHPT (n  = 25)	Patients with GEP-NET (n  = 34)	Patients without GEP-NET (n  = 67)	Patients with functioning pituitary adenoma (n  = 33)	Patients without functioning pituitary adenoma (n  = 68)	Patients without the three main MEN1 tumors (n  = 20)	Patients with only PHPT (n  = 30)	Patients with only GEP-NET (n  = 1)	Patients with only functioning pituitary adenoma (n  = 3)	Patients with PHPT and GEP-NET (n  = 18)	Patients with PHPT and functioning pituitary adenoma (n  = 14)	Patients with GEP-NET and functioning pituitary adenoma (n  = 1)	Patients with PHPT, GEP-NET and functioning pituitary adenoma (n  = 14)
Demographic characteristic	Total patients (n  = 65)	Patients with PHPT (n  = 53)	Patients without PHPT (n  = 12)	Patients with GEP-NETs (n  = 23)	Patients without GEP-NETs (n  = 42)	Patients with functioning pituitary adenomas (n  = 22)	Patients without functioning pituitary adenomas (n  = 43)	Patients without the three main MEN1 tumors (n  = 8)	Patients with only PHPT (n  = 21)	Patients with only GEP-NET (n  = 1)	Patients with only functioning pituitary adenoma (n  = 2)	Patients with PHPT and GEP-NETs (n  = 13)	Patients with PHPT and functioning pituitary adenomas (n  = 11)	Patients with GEP-NETs and functioning pituitary adenomas (n  = 1)	Patients with PHPT, GEP-NETs and functioning pituitary adenomas (n  = 8)
Patients with bone and mineral metabolism-related biochemical parameters (n  = 101)
Age at biochemical data collection (years)	35.3 ± 16.2,range 11–80	38.3 ± 15.7,range 11–80	26.2 ± 14.5,range 11–60	40.9 ± 14.8,range 19–80	32.5 ± 16.2,range 11–74	36.0 ± 12.3,range 16–61	35.0 ± 17.8,range 11–80	22.6 ± 12.7,range 11–60	36.6 ± 17.7,range 11–74	42	40.3 ± 17.5,range 21–55	45.2 ± 15.6,range 26–80	36.0 ± 11.3,range 16–54	42	35.4 ± 13.5,range 19–61
Women (%)	57/101 (56.4)	43/76 (56.6)	14/25 (56.0)	17/34 (50.0)	40/67 (59.7)	22/33 (66.7)	35/68 (51.5)	10/20 (50.0)	20/30 (66.7)	1/1 (100)	2/3 (66.7)	5/18 (27.8)	8/14 (57.1)	1/1 (100)	10/14 (71.4)
Men (%)	44/101 (43.6)	33/76 (43.4)	11/25 (44.0)	17/34 (50.0)	27/67 (40.3)	11/33 (33.3)	33/68 (48.5)	10/20 (50.0)	10/30 (33.3)	0/1 (0)	1/3 (33.3)	13/18 (72.2)	6/14 (42.9)	0/1 (0)	4/14 (28.6)
Patients with DXA parameters (n  = 65)
Age at DXA data collection (years)	41.4 ± 16.3,range 13–79	42.9 ± 16.3,range 13–79	34.7 ± 15.5,range 15–60	45.2 ± 14.8,range 20–79	39.3 ± 16.9,range 13–73	39.1 ± 14.0,range 15–61	42.5 ± 17.4,range 13–79	31.3 ± 15.6,range 15–60	42.9 ± 18.4,range 13–73	43	41.0 ± 25.5,range 18–42	48.0 ± 15.3,range 26–79	37.9 ± 13.5,range 15–59	41	40.0 ± 15.0,range 20–61
Women (%)	38/65 (58.5)	28/53 (52.8)	10/12 (83.3)	12/23 (52.2)	26/42 (61.9)	13/22 (59.1)	25/43 (58.1)	7/8 (87.5)	12/21 (57.1)	1/1 (100)	1/2 (50.0)	5/13 (38.5)	6/11 (54.5)	1/1 (100)	5/8 (62.5)
Men (%)	27/65 (41.5)	25/53 (47.1)	2/12 (16.7)	11/23 (47.8)	16/42 (38.1)	9/22 (40.9)	18/43 (41.9)	1/8 (12.5)	9/21 (42.9)	0/1 (0)	1/2 (50.0)	8/13 (61.5)	5/11 (45.5)	0/1 (0)	3/8 (37.5)

GEP-NETs, gastro-entero-pancreatic neuroendocrine tumors; PHPT, primary hyperparathyroidism.